These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Sasaki M; Sato Y; Nakanuma Y Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656 [TBL] [Abstract][Full Text] [Related]
3. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281 [TBL] [Abstract][Full Text] [Related]
5. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647 [TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of intrahepatic cholangiocarcinoma. Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346 [TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729 [TBL] [Abstract][Full Text] [Related]
9. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas. Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212 [TBL] [Abstract][Full Text] [Related]
10. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820 [TBL] [Abstract][Full Text] [Related]
11. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137 [TBL] [Abstract][Full Text] [Related]
12. Frequency of TERT promoter mutations in primary tumors of the liver. Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585 [TBL] [Abstract][Full Text] [Related]
14. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma. Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232 [TBL] [Abstract][Full Text] [Related]
17. Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma. Huang WC; Tsai CC; Chan CC J Formos Med Assoc; 2017 Jun; 116(6):464-468. PubMed ID: 27745798 [TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Zhang N; Zhao Z; Long J; Li H; Zhang B; Chen G; Li X; Lv T; Zhang W; Ou X; Xu A; Huang J Oncol Rep; 2017 Dec; 38(6):3650-3658. PubMed ID: 29130106 [TBL] [Abstract][Full Text] [Related]
19. Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations. Sasaki M; Sato Y; Nakanuma Y Am J Surg Pathol; 2019 Mar; 43(3):352-360. PubMed ID: 30520820 [TBL] [Abstract][Full Text] [Related]
20. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]